Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Rezvani

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Blood Advances|November 20, 2019
Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy studyAshrit Multani, Libby S Allard, Tamna Wangjam, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2013
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomesAndrew R Rezvani, Jeannine S McCune, Barry E Storer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Impact of donor age on outcome after allogeneic hematopoietic cell transplantationAndrew R Rezvani, Barry E Storer, Katherine A Guthrie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 3, 2011
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantationAndrew R Rezvani, Barry E Storer, Rainer F Storb, et al.
Transplantation and Cellular Therapy|July 17, 2021
Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent PatientsClaudio G Brunstein, Todd E DeFor, Ephraim J Fuchs, et al.
Transplantation and Cellular Therapy|April 9, 2025
Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access ProgramMitchell E Horwitz, Gary J Schiller, Stephanie B Tsai, et al.
Blood Advances|March 25, 2018
Infusion of donor-derived CD8<sup>+</sup> memory T cells for relapse following allogeneic hematopoietic cell transplantationLori Muffly, Kevin Sheehan, Randall Armstrong, et al.
Journal of Hematology & Oncology|June 14, 2017
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaNarendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, et al.
American Journal of Hematology|April 25, 2024
Management of post-autologous transplant relapse in patients with T-cell lymphomasOlivier Veilleux, Francisco Socola, Sally Arai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2008
Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host diseaseMary E D Flowers, Barry Storer, Paul Carpenter, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Blood Advances|November 20, 2019
Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy studyAshrit Multani, Libby S Allard, Tamna Wangjam, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2013
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomesAndrew R Rezvani, Jeannine S McCune, Barry E Storer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2014
Impact of donor age on outcome after allogeneic hematopoietic cell transplantationAndrew R Rezvani, Barry E Storer, Katherine A Guthrie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 3, 2011
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantationAndrew R Rezvani, Barry E Storer, Rainer F Storb, et al.
Transplantation and Cellular Therapy|July 17, 2021
Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent PatientsClaudio G Brunstein, Todd E DeFor, Ephraim J Fuchs, et al.
Transplantation and Cellular Therapy|April 9, 2025
Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access ProgramMitchell E Horwitz, Gary J Schiller, Stephanie B Tsai, et al.
Blood Advances|March 25, 2018
Infusion of donor-derived CD8<sup>+</sup> memory T cells for relapse following allogeneic hematopoietic cell transplantationLori Muffly, Kevin Sheehan, Randall Armstrong, et al.
Journal of Hematology & Oncology|June 14, 2017
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaNarendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, et al.
American Journal of Hematology|April 25, 2024
Management of post-autologous transplant relapse in patients with T-cell lymphomasOlivier Veilleux, Francisco Socola, Sally Arai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 2, 2008
Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host diseaseMary E D Flowers, Barry Storer, Paul Carpenter, et al.
Pageof 7